Abstracts tagged "B cells and MicroRNA"

Abstract Number: 2106 • 2016 ACR/ARHP Annual Meeting
Regulation of Marginal Zone B Cell Differentiation By microRNA-146a
Jennifer K. King¹, May Paing², Nolan Ung², Jorge Contreras², Michael Alberti², Thilini Fernando², Kelvin Zhang², Matteo Pellegrini² and Dinesh Rao², ¹Medicine, Rheumatology, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: B cell development in the bone marrow is followed by specification into several functional subsets in the spleen, including marginal zone B (MZB) cells…
Abstract Number: 2107 • 2016 ACR/ARHP Annual Meeting
Targeting Mir-155 in Rheumatoid Arthritis B Cells Reduces Antibody Production
Mariola Kurowska-Stolarska¹, Iain B McInnes², Stefano Alivernini³, Aziza Elmesmari⁴, Gianfranco Ferraccioli⁵, James Reilly² and David W. McCarey^6,7, ¹Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ⁶Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁷Centre for Rheumatic Diseases, Centre for Rheumatic Diseases, Glasgow, United Kingdom
Background/Purpose: Better understanding of epigenetic regulatory mechanisms in RA pathogenesis will facilitate the development of new biomarkers or therapeutic strategies. MicroRNAs are post-transcriptional regulators that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].